Low-dose radiation therapy: a treatment for pneumonia resulting from COVID-19

Hamid Ghaznavi1,2, Farideh Elahimanesh1, Jamil Abdolmohammadi1, Meysam Mirzaie1 and Sadegh Ghaderi2

1Department of Radiology, Paramedical School, Kurdistan University of Medical Sciences, Sanandaj, Kurdistan, Iran and 2Department of Neurosciences and Addiction Studies, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran

Abstract

Background: The Coronavirus disease 2019 (COVID-19) is spreading rapidly throughout the world. Lung is the primary organ which the COVID-19 virus affects and leads to pneumonia, an acute respiratory distress syndrome. COVID-19 infects the lower respiratory system, and the lung’s response to this infection is recruiting macrophages and monocytes leading to inflammation, this response causes widespread damage to the lung’s airways.

Aim: The purpose of this study is to review studies of using low-dose radiation as a treatment for the inflammation of the tissue and pneumonia resulting from COVID-19. These studies were compared with the risk of developing lung cancer during performed dose for the treatment of COVID-19 in radiation therapy.

Materials and methods: Our study focused on in vitro, in vivo and clinical reports of using low-dose radiation for the treatment of inflammation, pneumonia and COVID-19. The risk of lung cancer resulting from suggested dose in these studies was also evaluated.

Conclusion: From the review of articles, we have found that low-dose radiation can lead to improvement in inflammation in different line cells and animals; in addition, it has been effective in treating inflammation and pneumonia caused by COVID-19 in human up to 80%. Since suggested doses do not remarkably increase the lung cancer risk, low-dose radiation can be an adjuvant treatment for COVID-19 patients.

Introduction

The Coronavirus disease 2019 (COVID-19) is spreading rapidly throughout the world. By 9 September 2020, 27,784,361 people have been infected by COVID-19; moreover, 902,762 of these patients have died.1 Lung is the primary organ which the COVID-19 virus affects and leads to pneumonia, an acute respiratory distress syndrome (ARDS). In ARDS patients, overexpression of pro-inflammatory cytokines, such as interleukin, and macrophage inflammatory protein have been seen. This process is called ‘cytokine storm’.1 COVID-19 infects the lower respiratory system, and the lung’s response to this infection is recruiting macrophages and monocytes leading to inflammation, this response causes widespread damage to the lung’s airways.2

Activating cytokines leads to the migration of macrophages and monocytes to parts of lung infected with the COVID-19 virus. Endothelial cells play a key role in the inflammation process. After irradiating these cells with low radiation doses (0.01–2 Gy), the monocyte adhesion is significantly enhanced, and the mechanism of this phenomenon activates tumor necrosis factor-α after irradiation.3

For mammalian cells, hyper-radiosensitivity and induced radioresistance are determined below 0.3 Gy and in the dose range of 0.3 Gy to 0.6 Gy, respectively.4 In our study, investigations on using low-dose radiation as a treatment for COVID-19 were evaluated, eventually these studies were compared with risk of lung cancer during performed dose for the treatment of COVID-19 in radiation therapy.

In this paper, we review the available literature on the use of low-dose radiation in improving inflammation and pneumonia. Hence, in vivo and in vitro studies evaluating the anti-inflammatory effects of low-dose radiation on different cell lines and animals, as well as twelve recent clinical studies, in which the effects of low-dose radiotherapy in the treatment of patients with coronavirus disease has been evaluated. The results of most of these clinical studies have not yet been published. Published paper for this literature review were identified by searching PubMed database from 1940 onwards with the following Medical Subject Heading terms ‘pneumonia’, ‘COVID-19’, ‘coronavirus’, ‘inflammation’, ‘low dose Radiotherapy’. Articles in English language were reviewed.
In vivo and In vitro Studies

The anti-inflammatory effect of radiation on the lungs is through modulation of cytokine and adhesion molecule expression on activated endothelial cells and leukocytes and on nitric oxide (NO) production and oxidative burst in activated macrophages and native granulocytes. The highest efficiency was reported at doses of 0.3–0.7 Gy.6

In addition, the in vitro studies suggest that low-dose radiation therapy (LD-RT) has a potent anti-inflammatory effect, inhibiting leukocyte–endothelial interactions at doses <0.7 Gy. In contrast, inflammatory and degenerative bone diseases in humans are treated with doses ranging from 0.3 to 1.5 Gy. Thus, using lower doses in the range 0.1–0.3 Gy could maximise anti-inflammatory effects and minimise toxicity.7

In vivo studies indicated that the effects of LD-RT on decreasing inflammation are realised by the effects of these radiations on endothelial cells, mononuclear cells and macrophages. The doses used in these studies were in the range of 0.3–1 Gy. Studies on animals whose lungs have been directly affected by bacterial and viral pneumonia have indicated that low-dose application has been able to significantly decrease mortality in animals that received low doses in one fraction in comparison to those which did not receive the dose.8–11

The Effects of Low-Dose Radiation on the Immune System

The effects of low-dose radiation (above or below 1 Gy) on the immune system are controversial. Animal studies show that low-dose irradiation (more than 1 Gy) may lead to immunosuppression. Doses above 1 Gy result in deficiency of haematopoietic stem cells, accelerated cell cycling of bone marrow precursors, decreased cell viability of mature blood cells and suppression of blood leukocyte levels.12,13 Blood samples of radiology workers ranging from 21 to 57 years who are exposed to long-term low ‘dose reveal that some immunological parameters such as levels of T lymphocytes, IgA, IgG and IgM are decreased.14

Single fraction or chronic low dose with total doses below 1 Gy has been performed recently. The results show that low doses 0.5 or 1 Gy to dendritic cells (DCs) have not had significant effects on dendritic cells cytokine release and T cell proliferation.15 Irradiation of dendritic cell at 0.02–1.0 Gy shows that the highest proliferation capacity of T cells occurs at 0.05 Gy through released cytokine by dendritic cells. In contrast, this range of irradiated dose has not had any effects on the maturation of dendritic cells.16

Clinical Aspects of Low-dose Radiation

The use of Roentgen rays with a dose of 100–150 Roentgen in the treatment of pneumonia in children has been studied long time ago. The results indicated that the use of this radiation in low doses can be effective in the treatment of this disease.17 The application of ionising radiation in the treatment of pneumonia has been studied since the beginning of the last century. The results of this study showed that the use of low doses was able to decrease mortality in these patients like other methods including serum therapy and drug treatments. The use of low doses with a mean of 50 Roentgen has been effective in the treatment of most patients suffering from pneumonia.18 In some countries, such as Germany, low-dose radiotherapy is applied as an acceptable remedy method for the treatment of non-malignant diseases such as inflammatory, degenerative, hyperplferative, functional and vascular diseases.19

The results of in vitro study of human lung tissue against 0.5–1 Gy radiation showed that this low dose could significantly decrease the secretion of interferon-gamma and increase the secretion of interleukin-10 in comparison to the control group that did not receive a dose. Thus, this series of events leads to the stimulation of macrophages in the lung tissue. The overall results of this study indicated that low doses could stimulate macrophages for eliminating tissue inflammation.20

Suggested Dose for COVID-19

The mentioned articles suggested different low doses for the treatment of pneumonia resulting from COVID-19. It was recently suggested that LDRT with a single acutely delivered dose to the lungs of 0.3–1 Gy of low-linear energy transfer radiation could be used to treat COVID-19 pneumonia with very low risk and avoiding normal tissue toxicities, this report is proposed 0.1 Gy or 0.07–2 Gy to the chest region for COVID-19-related pneumonia. This value of dose is derived from the historical use of ionising radiation for pneumonia.21

It was also suggested that a priming dose with a few mGy followed by a single dose of 0.1, 0.18 or 0.25 Gy could be used to treat COVID-19 pneumonia. A dose of 0.25 Gy was selected because it is lower than the maximum dose of 0.26 Gy/year from natural background radiation in Ramsar, Iran. This background dose in Ramsar is much higher than the global average; however, doctors in the area have not reported an increase in the incidence of cancers such as leukaemia. In addition, there was no significant difference in haematological parameters such as red and white blood cell counts, mean corpuscular volume and mean platelet volume in individuals living in this area compared to areas that received a much lower dose than Ramsar. Therefore, it is recommended to use doses higher than 0.3 Gy for the anti-inflammatory effects of radiation with low doses in order to be effective.22,23

Current Studies on Human for COVID-19

Currently, 12 different groups throughout the world are applying low doses in the treatment of COVID-19 in humans; however, 10 of these studies are not over yet. Table 1 summarises these studies. In these studies, after lung radiation with the recommended doses, patients are followed up; moreover, their results are evaluated in both primary and secondary outcomes. Primary outcomes related to the measurement of blood oxygen level, PaO2/FiO2 ratio (the ratio of arterial oxygen partial pressure to fractional inspired oxygen) and chest x-ray are in the period of one day to two weeks after radiation. Secondary outcomes included measurements of hospitalisation, day free of assisted mechanical aspiration, mortality are from a few weeks to a few months after irradiation.24

A clinical study was recently carried out on five patients with COVID-19 in the age range of 64–96 years, in which the patients’ lungs were exposed to 1.5 Gy of radiation in one fraction for 10–15 minutes. In four patients in the first 24 hours of exposure, their respiratory condition was quickly improved. The results of blood tests and imaging also confirmed the positive effect of low-dose radiation on COVID-19 treatment.25

Another study of five patients with COVID-19 aged over 60 years who underwent national COVID-19 therapy protocols showed that using 0.5 Gy of radiation in one fraction led to the improvement of four patients in the first few days after exposure.
In addition, they were discharged from the hospital with an average of 6 days, and no radiation toxicity was observed in these patients.26

| Title                                                                 | Location     | Dose  | Participations | Conditions | Interventions          | Estimated Study Completion Date |
|----------------------------------------------------------------------|--------------|-------|----------------|------------|------------------------|---------------------------------|
| Low Dose Radiotherapy for COVID-19 Pneumonitis (LOWRAD-Cov19)        | Madrid, Spain| ≤ 1 Gy| 41             | COVID-19   | Low-dose radiation      | 8 September 2020                |
| COVID-19 Pneumonitis Low Dose Lung Radiotherapy (COLOR-19)           | Brescia, Italy| 0.7 Gy| 30             | COVID-19   | Low-dose radiation      | 23 July 2022                    |
| Low Dose Pulmonary Irradiation in Patients With COVID-19 Infection of Bad Prognosis (COVRTE-19) | Castellon, Spain | 0.5–1 Gy | 41 | COVID-19 PneumoniaViral | Low-dose radiation | 31 March 2021 |
| Ultra Low Doses of Therapy With Radiation Applied to COVID-19        | Valencia, Spain | 0.8 Gy | 15             | Pneumonia, Viral Cytokine Storm | Low-dose radiation + drug | 21 April 2021 |
| Best Supportive Care With or Without Low Dose Whole Lung Radiation Therapy for the Treatment of COVID-19 (RESCUE1-19) | Georgia, United States | – | 52             | Pneumonia SARS* COVID-19 Infection | Low-dose radiation | 30 May 2022 |
| Low Dose Anti-inflammatory Radiotherapy for the Treatment of Pneumonia by COVID-19 | Tarragona, Barcelona Madrid, Spain | 0.5 Gy additional 0.5 Gy fraction 48 h later | 106 | Pneumonia, Viral | Low-dose radiotherapy + Drug | 1 July 2021 |
| Low Dose Whole Lung Radiation Therapy for Patients With COVID-19 and Respiratory Compromise (VENTED) | Ohio, USA | 0.8 Gy | 24             | COVID-19   | Low-dose radiation      | 31 December 2021               |
| Low Dose Radiation Therapy for Covid-19 Pneumonia                   | New Delhi, India | 0.7 Gy | 10             | COVID Pneumonia | Low-dose radiation | July 2020 |
| Radiation Eliminates Storming Cytokines and Unchecked Edema as a 1-Day Treatment for COVID-19 (RESCUE 1-19) | Clayton Hess, Emory University | – | 10             | SARS COVID Pneumonia | Low-dose radiation | 23 October 2020 |
| Lung Irradiation for COVID-19 Pneumonia                             | Boston, USA  | 1 Gy  | 48             | SARS-COVID-Pneumonia | Low-dose radiation | October 2020 |

In addition, they were discharged from the hospital with an average of 6 days, and no radiation toxicity was observed in these patients.26

**Lung Cancer Risk Resulted from Radiation Therapy**

According to articles previously published or are presently being published, the recommended dose for the treatment of COVID-19 pneumonia is in the range of 0.3–1.5 Gy; however, it is one of the controversies surrounding the use of low-dose ionising radiation in the COVID-19 treatment that can be discussed is the incidence of cancers such as lung, oesophagus and breast cancer.

Based on the present study, using BEIR VII model to estimate the risk of lung cancer at 0.5 Gy for patients with coronavirus disease aged 25, 45, 65 years and treated by low-dose radiation, the incidence of lung cancer can increase by 2.1%, 2.09% and 1.68%, respectively, for men, or almost three times for women. According to this model, with an increase in the dose received by the lungs, the risk of lung cancer increases linearly.27

**Conclusion**

A review of in vitro and in vivo studies showed that the use of low doses up to 1.5 Gy eliminates tissue inflammation and pneumonia by stimulating macrophages. Although completed clinical studies on the use of low doses in the treatment of COVID-19 are limited, the results of these studies have indicated that low-dose lung irradiation up to 80% has been effective in treating inflammation and pneumonia caused by COVID-19. The incidence risk of cancer resulting from ionising radiation may question the application of these radiations; nevertheless, calculations indicated that within the recommended dose range in clinical studies (up to 1 Gy), the risk of lung cancer did not remarkably increase. Since no definitive treatment has been found for COVID-19, it is recommended for patients with COVID-19 whose condition is deteriorating. Moreover, treatment protocols have not been able to help them. Thus, low-dose ionising radiation methods can be recommended to the patients and can make them aware of the risks of possible side effects from the radiation and the positive results that this
method has had so far. It is hoped that ongoing clinical studies using this method will be completed as soon as possible, and their results will be positive in COVID-19 treatment.

Acknowledgements. None.

Financial Support. None.

Conflicts of Interest. None.

References

1. Coronavirus cases, death, and recovered. http://www.worldometers.info.

2. Liu J, Li S, Liu J et al. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients. EBioMedicine 2020; 55: 102763.

3. Tay M Z, Poh C M, Rénia L, MacAry P A, Ng I F. The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol 2020; 20: 363–374.

4. Schröder S, Kriesen S, Paape D, Hildebrandt G, Manda K. Modulation of inflammatory immune reactions by low-dose ionizing radiation: Cytokine release of murine endothelial cells is dependent on culture conditions. J Immunol Res 2018; 2018, Article ID 2856518: 13.

5. Rödel F, Frey B, Gaipil U et al. Modulation of inflammatory immune reactions by low-dose ionizing radiation: molecular mechanisms and clinical application. Curr Med Chem 2012; 19 (12): 1741–1750.

6. Rödel F, Keilholz L, Herrmann M, Sauer R, Hildebrandt G. Radiobiological mechanisms in inflammatory diseases of low-dose radiation therapy. Int J Radiat Biol 2007; 83 (6): 357–366.

7. Arenas M, Sabater S, Hernández V et al. Anti-inflammatory effects of low-dose radiotherapy. Strahlentherapie und Onkologie 2012; 188 (11): 975–981.

8. Lieberman L, Hodes P, Leopold S. Roentgen therapy of experimental lobar pneumonia in dogs. Am J Med Sci 1941; 201 (1): 92–99.

9. Fried C. The roentgen treatment of experimental pneumonia in the guinea-pig. Radiology 1941; 37 (2): 197–202.

10. Dubin I, Baylin G, Gobble J W. The effect of roentgen therapy on experimental virus pneumonia; on pneumonia produced in white mice by swine influenza virus. Am J Roentgenol Radium Ther 1946; 55: 478–481.

11. Baylin G, Dubin I, Gobble J W. The effect of roentgen therapy on experimental virus pneumonia; on feline virus pneumonia. Am J Roentgenol Radium Ther 1946; 55: 473–477.

12. Yagunov A, Tokalov S, Chukhlovkin A, Afanassiev B. Animal Studies of Residual Hematopoietic and Immune System Injury from Low Dose/ Low Dose Rate Radiation and Heavy Metals. Bethesda, MD: Armed Forces Radiobiology Research Institute, 1998.

13. Seed TM, Inal C, Dobson M E et al. Accommodative responses to chronic irradiation: effects of dose, dose rate, and pharmacological response modifiers. Mil Med 2002; 167: 82–86.

14. Godekmerdan A, Ozden M, Ayar A, Gursu MF, Ozan AT, Serhatlioglu S. Diminished cellular and humoral immunity in workers occupationally exposed to low levels of ionizing radiation. Arch Med Res 2004; 35 (4): 324–328.

15. Jahns J, Anderegg U, Saalbach A et al. Influence of low dose irradiation on differentiation, maturation and T-cell activation of human dendritic cells. Mutat Res/Fund Mol Mech Mutagenesis 2011; 709: 32–39.

16. Shigematsu A, Adachi Y, Koike-Kiriyama N et al. Effects of low-dose irradiation on enhancement of immunity by dendritic cells. J Radiat Res 2007; 48 (1): 51–55.

17. Oppenheimer A. Roentgen therapy of interstitial pneumonia. J Pediatr 1943; 23 (5): 534–538.

18. Calabrese E J, Dhawan G. How radiotherapy was historically used to treat pneumonia: could it be useful today? Yale J Biol Med 2013; 86 (4): 555.

19. Seegenschmiedt M H, Micke O, Willich N. Radiation therapy for nonmalignant diseases in Germany. Strahlentherapie und Onkologie 2004; 180 (11): 718–730.

20. Meziani L, Robert C, Mordant P, Deutsch E. Low doses of radiation therapy increase the immunosuppressive profile of lung macrophages via IL-10 production and IFNγ/IL-6 suppression: a therapeutic strategy to counteract lung inflammation. bioRxiv 2020.

21. Kirkby C, Mackenzie M. Is low dose radiation therapy a potential treatment for COVID-19 pneumonia? Radiother Oncol 2020; 147 (146): 221.

22. Ghadimi-Moghadam A, Haghani M, Bevelacqua J et al. COVID-19 tragic pandemic: concerns over unintentional “directed accelerated evolution” of novel Coronavirus (SARS-CoV-2) and introducing a modified treatment method for ARDS. J Biomed Phys Eng, 2020; 10 (2): 241.

23. Ghiassi-Nejad M, Mortazavi S M J, Cameron J R, Niroomand-Rad A, Karam P A. Very high background radiation areas of Ramsar, Iran: preliminary biological studies. Health Phys 2002; 82 (1): 87–93.

24. COVID-19 and Low dose irradiation. https://www.clinicaltrials.gov. Accessed on Jun 2020.

25. Hess CB, Buchwald ZS, Stokes W et al. Low-Dose Whole-Lung Radiation for COVID-19 Pneumonia: Planned Day-7 Interim Analysis of a Registered Clinical Trial. medRxiv. 2020. doi: https://doi.org/10.1101/2020.06.03.20116988

26. Ameri A, Rahnama N, Bozorgmehr R et al. Low-dose Whole-Lung Irradiation for COVID-19 Pneumonia: Short Course Results. Int J Radiat Oncol Biol Phys 2020; 108 (5): 1134–1139. https://doi.org/10.1016/j.ijrobp.2020.07.026

27. Kirsch D G, Diehn M, Cucinotta F A, Weichselbaum R. Lack of supporting data make the risks of a clinical trial of radiation therapy as a treatment for COVID-19 pneumonia unacceptable. Radiother Oncol 2020. https://doi.org/10.1016/j.radonc.2020.04.060017-8140